Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2016’, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

The report reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics and enlists all their major and minor projects

The report assesses Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Adamis Pharmaceuticals Corp

Advaxis Inc

Ambrx Inc

Amgen Inc

Aptevo Therapeutics Inc

Armour Therapeutics Inc

ArQule Inc

Arrowhead Pharmaceuticals Inc

Arvinas Inc

Asana BioSciences LLC

AstraZeneca Plc

ATLAB Pharma SAS

Aurigene Discovery Technologies Ltd

Bavarian Nordic A/S

BeiGene Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

CellCentric Ltd

Clovis Oncology Inc

Corcept Therapeutics Inc

Corvus Pharmaceuticals Inc

Curevac AG

DexTech Medical AB

Eli Lilly and Company

Endocyte Inc

ESSA Pharma Inc

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Glactone Pharma AB

GlaxoSmithKline Plc

GTx Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

MedImmune LLC

Medivation Inc

MEI Pharma Inc

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Novartis AG

Oncogenex Pharmaceuticals Inc

Oncolytics Biotech Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Progenics Pharmaceuticals Inc

Selexel

Sotio as

Supratek Pharma Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Ltd

Tesaro Inc

Threshold Pharmaceuticals Inc

Tiltan Pharma Ltd

Tokai Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

UbiVac LLC

Viralytics Ltd

Zenith Capital Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 8

Therapeutics Development 9

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 11

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 15

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 16

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 19

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 25

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 26

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 87

Drug Profiles 101

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 433

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 438

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 441

Appendix 452

List of Tables

List of Tables

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 19

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Development, H2 2016 28

Products under Development by Companies, H2 2016 29

Products under Development by Companies, H2 2016 (Contd..1) 30

Products under Development by Companies, H2 2016 (Contd..2) 31

Products under Development by Companies, H2 2016 (Contd..3) 32

Products under Development by Companies, H2 2016 (Contd..4) 33

Products under Development by Companies, H2 2016 (Contd..5) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AB Science SA, H2 2016 36

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AbbVie Inc, H2 2016 37

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Adamis Pharmaceuticals Corp, H2 2016 38

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Advaxis Inc, H2 2016 39

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ambrx Inc, H2 2016 40

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Amgen Inc, H2 2016 41

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Aptevo Therapeutics Inc, H2 2016 42

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Armour Therapeutics Inc, H2 2016 43

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ArQule Inc, H2 2016 44

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 45

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Arvinas Inc, H2 2016 46

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Asana BioSciences LLC, H2 2016 47

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by AstraZeneca Plc, H2 2016 48

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ATLAB Pharma SAS, H2 2016 49

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 50

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 51

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by BeiGene Ltd, H2 2016 52

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 53

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 54

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Celgene Corp, H2 2016 55

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by CellCentric Ltd, H2 2016 56

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Clovis Oncology Inc, H2 2016 57

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Corcept Therapeutics Inc, H2 2016 58

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Corvus Pharmaceuticals Inc, H2 2016 59

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Curevac AG, H2 2016 60

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by DexTech Medical AB, H2 2016 61

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Eli Lilly and Company, H2 2016 62

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Endocyte Inc, H2 2016 63

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by ESSA Pharma Inc, H2 2016 64

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 65

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Gilead Sciences Inc, H2 2016 66

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Glactone Pharma AB, H2 2016 67

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 68

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by GTx Inc, H2 2016 69

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 70

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 71

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Johnson & Johnson, H2 2016 72

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by MedImmune LLC, H2 2016 73

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Medivation Inc, H2 2016 74

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by MEI Pharma Inc, H2 2016 75

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 76

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by NewLink Genetics Corp, H2 2016 77

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Novartis AG, H2 2016 78

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016 79

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Oncolytics Biotech Inc, H2 2016 80

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 81

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Pfizer Inc, H2 2016 82

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Progenics Pharmaceuticals Inc, H2 2016 83

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Selexel, H2 2016 84

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Sotio as, H2 2016 85

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Supratek Pharma Inc, H2 2016 86

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 87

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 88

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tesaro Inc, H2 2016 89

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Threshold Pharmaceuticals Inc, H2 2016 90

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tiltan Pharma Ltd, H2 2016 91

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Tokai Pharmaceuticals Inc, H2 2016 92

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 93

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by UbiVac LLC, H2 2016 94

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Viralytics Ltd, H2 2016 95

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline by Zenith Capital Corp, H2 2016 96

Assessment by Monotherapy Products, H2 2016 97

Number of Products by Stage and Target, H2 2016 99

Number of Products by Stage and Mechanism of Action, H2 2016 104

Number of Products by Stage and Route of Administration, H2 2016 108

Number of Products by Stage and Molecule Type, H2 2016 110

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects, H2 2016 443

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..1), H2 2016 444

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..2), H2 2016 445

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..3), H2 2016 446

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects (Contd..4), H2 2016 447

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products, H2 2016 448

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..1), H2 2016 449

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products (Contd..2), H2 2016 450

List of Figures

List of Figures

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 19

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Products, H2 2016 28

Assessment by Monotherapy Products, H2 2016 97

Number of Products by Top 10 Targets, H2 2016 98

Number of Products by Stage and Top 10 Targets, H2 2016 98

Number of Products by Top 10 Mechanism of Actions, H2 2016 103

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 103

Number of Products by Top 10 Routes of Administration, H2 2016 107

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 107

Number of Products by Top 10 Molecule Types, H2 2016 109

Number of Products by Stage and Top 10 Molecule Types, H2 2016 109

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports